Novo Nordisk ( Novo Nordisk )

Novo Nordisk

Novo Nordisk's picture

About Novo Nordisk

Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in eight countries, and affiliates or offices in 75 countries. Novo Nordisk is controlled by majority shareholder, Novo A/S, which holds approximately 25% of its shares and a majority 75% voting shares.

Novo Nordisk press release, blog etc

10/15/2018 - 08:54 Novo Nordisk appoints Ludovic Helfgott executive vice president Biopharm
10/12/2018 - 19:10 Fiasp is effective at controlling blood sugar levels in children and adolescents living with type 1 diabetes, when compared to conventional insulin aspart
10/02/2018 - 02:05 Ryzodeg offers a simpler solution with once-daily dosing and reduced risk of nocturnal hypoglycaemia vs insulin glargine U100 plus insulin aspart
10/02/2018 - 00:58 People with diabetes may achieve improved glycaemic control with Tresiba versus glargine U100, without an increase in hypoglycaemia
10/02/2018 - 00:32 Addressing social and cultural drivers of type 2 diabetes is key to its treatment and prevention
10/01/2018 - 08:42 Novo Nordisk to establish California manufacturing site for stem cell-based therapies
10/01/2018 - 08:30 Novo Nordisk plans first global launch of connected insulin pens and announces key digital health partnerships
09/27/2018 - 20:27 International Diabetes Federation (IDF) global survey reveals 2 in 3 people with type 2 diabetes have cardiovascular disease risk factors and/or have experienced a cardiovascular event
09/27/2018 - 19:51 New phase 2 data for somapacitan demonstrate its potential as an efficacious once-weekly treatment for childhood growth hormone deficiency
09/23/2018 - 23:08 Danish Government and Novo Nordisk first to partner with UN-anchored initiative on non-communicable diseases
09/20/2018 - 12:08 Novo Nordisk - Oral semaglutide demonstrates greater reductions in HbA1c and body weight and comparable number of adverse events vs dulaglutide in Japanese people with type 2 diabetes
09/18/2018 - 12:13 Novo Nordisk announces plans to transform its approach to Research & Development
08/26/2018 - 10:43 Ozempic consistently reduced the risk of major cardiovascular events across type 2 diabetes populations at high CV risk regardless of prior CV events at baseline
08/20/2018 - 04:41 Oral semaglutide provides superior HbA1c and weight reductions versus placebo in people with type 2 diabetes and renal impairment in the PIONEER 5 trial
08/17/2018 - 02:21 Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins
08/10/2018 - 02:18 Novo Nordisk A/S purchases B shares worth DKK 954 million from Novo Holdings A/S under the 2018 share repurchase programme
08/09/2018 - 03:02 Diabetes Care Type 1 Type 2 Gestational diabetes Pens, needles and injection support
08/08/2018 - 07:42 Diabetes Type 1 Type 2 Gestational diabetes Pens, needles and injection support